- Details
- Press Release
Sabinsa Achieves USP GMP Audited Status for Three Additional Sites
Three additional Sami-Sabinsa Group Manufacturing units have been audited by the United States Pharmacopeia (USP) and received GMP compliance certificates for the Kunigal unit and the Dobaspet unit, both in Bengaluru, India, and the Hyderabad unit in Telangana state, India. The company’s Nelamangala site in Bengaluru received a USP GMP certificate earlier this year. All four sites are certified Halal by The Islamic Food and Nutrition Council of America (IFANCA) and OK Kosher, with the Kunigal and Hyderabad units NSF-GMP certified as well.
- Details
- Press Release
Sabinsa’s Curcumin C3 Complex® Identified as the Most Studied
A retrospective analysis of curcumin research presented a comprehensive look at the vast body of science on the popular extract of turmeric. Curcumin: Total-Scale Analysis of the Scientific Literature by Dr. Atanas G. Atanasov et al, a bibliometric review of literature on curcumin published in the April 2019 edition of the journal, Molecules (2019, 24, 1393), discussed investigations into a range of clinical indications, including Alzheimer’s disease, psoriasis vulgaris, obesity, oral lichen planus, osteoarthritis, inflammation associated with metabolic syndrome, and radiation dermatitis as well as for modulation of human gut microbiome.
- Details
- Press Release
Sabinsa Staff Available at Booth # 317
Sabinsa will feature two new patent-protected branded ingredients at New York Society of Cosmetic Chemists (NYSCC) Suppliers’ Day tradeshow May 7 – 8, 2019, at the Jacob K. Javits Convention Center in New York City. This important event attracts science and chemistry research management and staff, purchasing agents, and top management representing major cosmetic giants as well as small and start-up companies.
- Details
- Press Release
Grant Aids Sami Labs to Test Plant Species and Evaluate Commercial Viability in a Sustainable Manner
The Department of Scientific and Industrial Research (DSIR), under the Government of India’s Ministry of Science and Technology has sanctioned funding to Sabinsa’s parent company Sami Labs for research on “Development and standardization of manufacturing processes for large scale production of valuable secondary metabolites from callus-derived cells of vascular cambial explants of selected woody plant species.”
- Details
- Press Release
The Sami-Sabinsa Group’s Nelamangala biotechnology site in Bengaluru, India has been audited by the United States Pharmacopeia (USP) and received a GMP compliance certificate on February 25, 2019.